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Ponies suffering from recurrent episodes of laminitis when grazed at pasture (pasture-
associated laminitis) exhibit phenotypes similar to those associated with human metabolic 
syndrome. In humans, evidence suggests that the obesity-related morbidities associated with 
metabolic syndrome, including diabetes and cardiovascular disease, are caused by an increase 
in the production of advanced glycoxidation end-products (AGEs). These end-products have 
been recognised as putative pro-inflammatory mediators and are considered a ‘risk factor’ for 
human health. However, the evaluation of AGEs in laminitic ponies has not been explored. 
 
The aim of this study was to compare plasma concentrations of the AGE pentosidine (PENT) 
in ponies presenting with clinical features of equine metabolic syndrome (EMS) with a 
history of recent laminitis and/or showing signs of laminitis at the time of sampling (LP) with 
those with no prior history of clinical laminitis (NL). Age, body condition score (BCS) and 
bodyweight were recorded and blood samples collected for the measurement of plasma 
concentrations of PENT, glucose, insulin, triglycerides (TG), non-esterified fatty acids 
(NEFA) and cortisol. Insulin sensitivity was assessed by the reciprocal of the square root of 
insulin (RISQI) and the insulin:glucose ratio. Plasma PENT concentrations were twofold 
higher (P < 0.005) in LP than in NL ponies. Significant (P < 0.05) correlations were also 
evident between PENT and insulin, RISQI, TG and age. These preliminary findings are 
consistent with the hypothesis that glycoxidation in laminitis is associated with EMS. 
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It has recently been observed that ponies prone to recurrent episodes of laminitis when grazed 
at pasture (pasture-associated laminitis) exhibit a phenotype similar to human metabolic 
syndrome (HMS) (Treiber et al., 2006 and Geor, 2008). In HMS, the clustering of obesity 
(especially visceral adiposity), insulin resistance (IR), atherogenic dyslipidaemia and elevated 
blood pressure, and evidence of pro-inflammatory and pro-thrombotic states have been 
associated with a fivefold increase in the risk of type 2 diabetes mellitus (Alberti et al., 2005 
and Potenza and Mechanick, 2009). Similarly, the clustering of obesity, regional 
accumulations of fat, IR, hyperleptinaemia and hyperinsulinaemia predicts an increase in the 
risk of pasture-associated laminitis in ponies presenting this metabolic syndrome phenotype 
(equine metabolic syndrome, EMS) (Geor, 2008). 
 
It is widely hypothesised that IR and its associated hyperinsulinaemia are pivotal in the 
pathological manifestations of metabolic syndrome, particularly in the susceptibility to 
laminitis. Indeed, clinical and histopathological laminitis can be induced experimentally in 
horses and ponies by use of a euglycaemic hyperinsulinaemic clamp (Asplin et al., 2007 and 
de Laat et al., 2010), a model which allows the developmental and acute stages of 
hyperinsulinaemic laminitis to be studied. Furthermore, this insulin-induced model of 
laminitis was recently shown to be associated with the accumulation of advanced 




In human medicine, AGEs have been recognised as putative pro-inflammatory mediators 
(Galli et al., 2005) and considered a ‘risk factor’ for human health. AGEs are produced by the 
Maillard reaction in food or endogenously (Grunwald et al., 2006). The formation of AGEs 
involves not only the metabolic reduction of carbohydrates (glucose, galactose, fructose, 
ribose), but also the intermediates of glucose metabolism (such as glucose-6-phosphate, 
fructose-6-phosphate, and glyceraldehyde), lipid peroxidation molecules, metabolites of the 
polyol pathway (fructose or fructose 3-phosphate) and carbonyl compounds; these reactions 
involve also the formation of reactive oxygen species (ROS). AGEs may in turn activate their 
receptors leading to inflammation through nuclear factor κB signalling (Bierhaus et al., 2001), 
increasing oxygen free radical formation and the induction and release of pro-inflammatory 
cytokines, adhesion molecules and growth factors (Bierhaus et al., 1998). The accumulation 
of AGEs is associated with the pathogenesis of chronic conditions, like diabetes mellitus 
(Singh et al., 2001), due to the hyperglycaemic condition. However, AGEs can also be 
produced under euglycaemic conditions since they can be formed as a result of oxidant stress 
and along inflammatory pathways (Yan et al., 2003). 
 
In contrast to humans, diabetes mellitus is rare in horses, although insulin resistance (IR) in 
horses and ponies is being increasingly recognised (Geor, 2008). Increases in the circulating 
concentrations of AGEs have been associated with IR in non-obese, non-diabetic human 
subjects (Tan et al., 2011). As AGE formation is inevitable under pathophysiological 
conditions (Sanguineti et al., 2008) and laminitis-prone ponies suffer from a naturally 
occurring disorder that resembles the HMS, the question arises whether glycoxidation plays 
an explicit role in laminitis. One of the well-characterised AGEs is pentosidine (PENT), 
which is considered to be a major glycoxidative end-product (Suliman et al., 2003) and is 
 
 
widely used as a measure of total AGE accumulation in plasma or other tissues (van Deemter 
et al., 2009). 
 
The objective of the present study was therefore to test the hypothesis that the glycoxidation 
cascade plays a role in EMS-associated laminitis. Plasma concentrations of AGE pentosidine 
were determined in ponies with no prior history of clinical laminitis (NL) and compared with 
those in ponies exhibiting clinical features of EMS and with a recent history of laminitis 
and/or showing signs of laminitis at the time of sampling (LP). According to the above 
hypothesis, if the glycoxidation cascade plays a role in EMS-associated laminitis, increased 
PENT concentrations would be expected in the plasma of LP ponies. We also investigated the 
possible relationship between plasma PENT concentrations and other metabolic variables 
typically altered in EMS. To the authors’ knowledge, the production of AGE pentosidine in 
ponies affected by EMS and laminitis has not been previously studied or reported. 
Materials and methods 
Animals and selection criteria 
 
All procedures were approved by the Virginia Tech Institutional Animal Care and Use 
Committee. The samples included in the study were collected during the spring season 
(March to May) from 31 ponies (28 females, 1 stallion, 2 geldings), all of which belonged to a 
previously studied herd (Carter et al., 2009b and Treiber et al., 2006). 
 
Thirty of the animals were Welsh or Dartmoor Pony pure breeds, and one animal was a cross-
breed; all ponies descended from pony bloodlines residing on the selected farm. All ponies 
were maintained under similar pasture conditions composed of mixed grass (fescue, orchard 
grass and Kentucky bluegrass) and legume (clover) species; ponies were not provided with 
 
 
supplemental feeds (average nutrient composition of the pasture forage is reported in Table 
1). 
The criteria for inclusion in the study were based on the presence or absence of a history of 
clinical laminitis based on farm records. Ponies were excluded from the study if clinical 
examination exposed evidence of pituitary pars intermedia dysfunction (PPID). The screening 
for PPID included the measurement of plasma adrenocorticotrophic hormone (ACTH) 
concentrations; this measurement was performed in March (Animal Health Diagnostic Center, 
Cornell University, Ithaca, New York). All ponies included in the study had plasma ACTH 
levels within the laboratory reference range (9–35 pg/mL). Ponies that had never shown any 
clinical signs of laminitis up until the time of sampling were classified as never laminitic (NL) 
(n = 10). The laminitic ponies (LP) group included animals that had experienced at least one 
episode of laminitis during the 12-month period prior to sampling (n = 9) and/or were 
showing signs of laminitis just prior to sampling (n = 12), diagnosed by an experienced 
veterinarian. All LP (n = 21) exhibited other clinical features of EMS, including obesity 
and/or regional adiposity and previous evidence of hyperinsulinaemia. 
Clinical data and blood sampling 
 
Ponies were brought in from pasture the night (approximately 20:00 h) prior to their 
examination and sampling. Ponies were housed in a dry lot and provided group access to a 
small quantity (∼0.5 kg per head) of orchard-grass hay (dry matter basis: crude protein 
11.5%, acid detergent fibre 39%, neutral detergent fibre 59%, water-soluble carbohydrates 
5.1% and starch 1.5%). No other feed or forage was offered until after completion of 
sampling. At 07:00 h, ponies were temporarily housed in 3 × 3 m stalls and blood samples 
were collected between 08:00 and 10:00 h. Blood samples were collected by jugular 
venepuncture into 10 mL Vacutainer tubes containing K-EDTA and sodium heparin as 
 
 
anticoagulant (Becton, Dickinson). Samples were placed immediately onto ice and 
centrifuged within 30 min of sampling at 3000 g. Plasma fractions were then drawn off and 
stored at −80 °C until analysis. 
 
All ponies were weighed on an electronic weighing scale and their body condition score 
(BCS) calculated according to a 1–9 scale, whereby 1 indicated emaciation and 9 indicated 
extremely fat (Henneke et al., 1983). In this population of ponies, a BCS between 4 and 6 was 
classified as a moderate body condition, while a BCS exceeding 6 was classified as obese 
(Carter et al., 2009a). 
Samples analyses 
 
Plasma samples were analysed for glucose, triglyceride, non-esterified fatty acid (NEFA) and 
insulin concentrations, as previously described (Treiber et al., 2006 and Carter et al., 2009b). 
In brief, plasma glucose (G), triglycerides (TG) and NEFA were analysed by use of an 
automated analyser (Beckman Instruments) and enzymatic assay kits (Triglyceride GPO 
reagent; Glucose Procedure No. 16-UV, Sigma Diagnostics; NEFA, Wako Autokit). Plasma 
insulin concentrations were determined by use of a radioimmunoassay (RIA) previously 
validated for equine insulin (Coat-A-Count Insulin, Diagnostic Products) (Freestone et al., 
1991), and cortisol concentrations were determined using an RIA (Coat-A-Count Cortisol, 
Diagnostic Products) previously validated for equine cortisol (Alexander and Irvine, 1998). 
All assays were performed in duplicate. 
Calculation of basal proxies 
 
Basal values of plasma insulin and glucose were used to calculate the following two proxies 
of insulin sensitivity (as previously described in Treiber et al., 2005): (1) the reciprocal of the 
 
 
square root of insulin (RISQI) = 1/√basal insulin concentration; and (2) the basal insulin to 
glucose ratio (I:G = insulin/glucose) (Treiber et al., 2005). 
Pentosidine analyses 
 
Plasma pentosidine concentrations were measured by high performance liquid 
chromatography (HPLC), following the method of Odetti et al. (1992) with slight 
modifications. Briefly, chromatography was performed using a Waters HPLC system 
equipped with a Waters 570 fluorimeter detector. Each sample was hydrolysed with 6 mol/L 
hydrochloric acid (VWR International) for 18 h at 110 °C in borosilicate screw-capped tubes, 
dried in a Speed-Vac concentrator and then reconstituted in HPLC-grade water containing 
0.01 mol/L heptafluorobutyric acid (HFBA, Pierce Prodotti Gianni), filtered and injected into 
a Waters C18 XTerra Reverse-Phase column (25 cm × 0.46 cm, 5 μm) with a curvilinear 
gradient program. Pentosidine peaks were monitored using a fluorescent detector at λex 335 
nm and λem 385 nm wavelengths. A pentosidine synthetic standard (prepared as described by 
Grandhee and Monnier, 1991) was injected at the start of each run to determine the 
pentosidine concentration in the sample by peak area comparison. The amount of pentosidine 
was expressed as pmol per mg of plasma protein content. 
Protein content determination 
 
Plasma protein content was determined using the BCA protein assay kit according to the 
manufacturer’s instructions (Thermo Scientific). 
Statistical analysis 
 
All statistical analyses were performed using Graph Pad Prism 4.0 software (Graph Pad 
Software). The assumption of normality was tested using the Kolgoromov–Smirnov test. 
 
 
Statistical significance was considered at P ⩽ 0.05. Normally distributed variables were 
expressed as means plus standard deviations, while non-normally distributed variables were 
expressed as medians plus interquartile ranges (IR). The Mann–Whitney U test was used to 
compare LP and NL group data for plasma concentrations of pentosidine, insulin, 
triglycerides, glucose, NEFA and cortisol, as well as values of RISQI, I:G, BCS, animal age 
and bodyweight (BW). Finally, the relationships between plasma concentrations of 
pentosidine and the other metabolic parameters were investigated using the one-tailed 





The mean age, BW and BCS for each experimental group are reported in Table 2. LP ponies 
were older (P < 0.001) than NL ponies. No statistical differences were detected between 
groups for BCS or BW. Ninety per cent (19/21) of the LP and 80% of the NL ponies (8/10) 
were considered obese (BCS > 6). All other ponies fell into the moderate body condition 
category (BCS >than 4 and ⩽6). 
 
Plasma biochemical analytes 
The results for the biochemical analyses of plasma samples are reported in Table 2. No 
significant differences were detected between LP and NL ponies for either plasma glucose or 
NEFA. Plasma concentrations of triglycerides were significantly higher in LP than in NL 
ponies (P = 0.03) as were those of insulin. Cortisol measurements were available for just 19 
subjects (NL n = 9; LP n = 11); no differences were detected (P = 0.40) (10.07 [9.25–11.72] 




Mean values of plasma pentosidine were almost twofold higher in the LP (9.75 ± 0.98 
pmol/mg protein) than in NL ponies (5.26 ± 0.79 pmol/mg protein, P < 0.005) ( Table 2). 
Insulin sensitivity 
 
The proxy measurement of insulin sensitivity (RISQI) was significantly lower in the LP group 
(P < 0.001). Moreover, the I:G ratio was significantly higher in LP than in NL ponies, 
suggesting the existence of insulin resistance in the laminitic ponies ( Table 2). 
Components of EMS associated with plasma PENT 
 
Combining the data from the two groups, positive correlations transpired for plasma 
concentrations of PENT vs. insulin (rs = +0.69, P < 0.001), PENT vs. I:G (rs = +0.64, P < 
0.01), and PENT vs. TG (rs = +0.33, P < 0.03); a negative correlation was observed between 
PENT and RISQI score (rs = −0.56, P < 0.0005) ( Fig. 1). No significant correlation existed 






The present study is the first to associate a marker of glycoxidation (plasma PENT 
concentration) with EMS-associated laminitis and to identify relationships between plasma 
PENT concentrations and various metabolic variables typically altered in EMS. Consistent 
with previous findings from this group of ponies (Treiber et al., 2006 and Carter et al., 
2009b), the LP ponies exhibited hyperinsulinaemia, in comparison with NL ponies (P < 
 
 
0.001), and insulin resistance, as suggested by a significantly lower RISQI (P < 0.001) and 
higher I:G ratio (P < 0.001), as well as hypertriglyceridaemia (P < 0.03). 
 
In the current study, the basal proxy RISQI was used as this measure has been shown to be 
negatively correlated to insulin sensitivity determined by the more rigorous minimal model 
method (Treiber et al., 2005). While being less invasive and more feasible, the accuracy of 
proxy measures has been questioned. Proxy measurements of insulin sensitivity used in man 
are based on fasting glucose and insulin concentrations, which ensures a steady state of 
insulinaemia (Muniyappa et al., 2008). One limitation of the current study was that the ponies 
were provided access to a small amount of hay during the overnight period prior to blood 
sampling. This small quantity of hay was provided to counter stress associated with removal 
from pasture and also in recognition of the fact that horses evolved to graze with short fasting 
state no longer than 3–5 h at a time (Ralston, 1984). Arguably, between-pony differences in 
hay consumption during the night-time hours may have accounted for some of the group 
variation in outcome measures. However, any effect on measured variables (e.g. glucose and 
insulin concentrations) was likely minimal given the small amount of hay provided and its 
very low NSC content. 
 
Recent studies have identified metabolic risk factors for laminitis, but as yet it has not been 
determined which of these factors is critical for the onset of clinical laminitis even if 
hyperinsulinaemia could play an important role (Asplin et al., 2007 and de Laat et al., 2010). 
According to de Laat et al. (2012), a significant accumulation of AGEs is evident in the 
lamellae of horses following 48 h hyperinsulinaemic clamp technique, which induces Obel 
grade 2 laminitis in Standardbred horses. The same authors reported a failure to detect an 
increase in oxidative protein damage (protein carbonyl) and cellular lipid peroxidation 
 
 
(MDA) during the induction of laminitis. Limited evidence of oxidative stress was also 
reported for more chronic forms of endocrinopathic laminitis (Keen et al., 2004 and Treiber et 
al., 2009). 
 
The higher plasma concentrations of pentosidine in LP compared to NL ponies suggested that 
glycoxidation may play a role in the pathogenesis of EMS and its related laminitis. Plasma 
pentosidine is a reliable marker of the glycoxidation cascade (Nitti et al., 2005). The 
accumulation of AGEs in tissues significantly increases the level of inflammation in the body 
(Bengmark, 2007). AGEs induce chemical modifications and the cross-linking of tissue 
proteins, mediating various tissue dysfunctions and causing the release of pro-inflammatory 
molecules and cytokines through their interaction with specific AGE receptors (Sanguineti et 
al., 2008). 
 
Previous studies have stated that ageing could play a role in the development of laminitis 
(Alford et al., 2001). Indeed, the animals of the LP group of the present study were older than 
the ponies of the NL group (P < 0.001). As laminitis may be an age-related disease, especially 
in animals with PPID, it is possible that glycoxidative damage could contribute to an 
increased total AGE burden in the face of an inability to excrete these compounds ( Uribarri et 
al., 2007). Additionally, none of the ponies had clinical evidence of PPID, and plasma ACTH 
concentrations were within the laboratory reference range. 
 
Pentosidine was first studied in collagen as a marker of glycoxidation rate. Levels of 
pentosidine can increase with age in different mammalian species, presenting an inverse 
correlation between species longevity and glycoxidation rates (Sell et al., 1996). In horses, 
previous studies have reported the accumulation of pentosidine with age in joint cartilage 
 
 
specimens (Brama et al., 2000), as well as in tendons within the sesamoid region (Lin et al., 
2005). In the present study, no significant correlation between pentosidine and animal age 
was detected, even if LP ponies were twice the age of the NL cases. This result might be due 
to the fact that plasma is not the best ‘tissue’ for studying the link between AGEs 
accumulation and ageing. Tissue components that exhibit a slow turnover, such as skin 
collagen (Sell et al., 1996), are more suitable to evaluate the effect of ageing. Nonetheless, it 
is unlikely that the higher PENT concentrations in the LP group is simply due to an effect of 
ageing as studies in healthy humans have demonstrated a only small differences in plasma 
pentosidine between subjects in their 20s vs. those in their 90s (Odetti et al., 2005). 
 
Alternatively, a more significant increase of PENT was observed with a metabolic 
disturbances, such as diabetes. It is interesting to note that the plasma concentrations of PENT 
in human diabetic patients are much lower (2.09 ± 0.16 pmol/mg) (Sugiyama et al., 1998) 
than the concentrations measured in the LP and NL ponies. In human diabetes, 
hyperglycaemia and the auto-oxidation of glucose provides substrate for the glycoxidative 
stress pathway. However, persistent hyperglycaemia and diabetes mellitus are apparently rare 
in horses (Johnson et al., 2005 and Durham et al., 2009), suggesting that factors other than 
glucose (e.g. insulin) could potentially lead to the increase in AGEs. 
 
Each tissue responds to high concentrations of AGEs in different ways (Nitti et al., 2005). In 
horses, the level of superoxide dismutase (SOD) (an antioxidant enzyme) in the lamellae is 
reportedly low (Loftus et al., 2007), which could make the laminar tissues more susceptible to 
glycoxidative damage. The interactions between AGEs with their specific receptor (RAGE) 
may be linked to the increased generation of ROS by multiple mechanisms such as by 
decreasing the activity of SOD and catalase, diminishing glutathione stores, or the activation 
 
 
of protein kinase C (Ramasamy et al., 2005). Glycoxidation may contribute to endothelial 
dysfunction (Chappey et al., 1997), the cross-linking of collagen and interstitial matrix with 
reduced turnover and functionality (Avery and Bailey, 2006), the increased release of 
cytokines that contributes to inflammation and tissue damage (Bengmark, 2007) and to the 
worsening of insulin resistance (Sandu et al., 2005). 
 
The identification of higher plasma PENT levels in the laminitic group of ponies is a 
promising result for the study of the inflammatory nature of equine metabolic syndrome and 
laminitis since AGEs are well-known pro-oxidant and pro-inflammatory molecules. As the 
incidence of pasture-associated laminitis tends to be highest during the spring and early 
summer, in association with the peak accumulation of non-structural carbohydrates in pasture 
forage (Hoffman et al., 2001, Kronfeld et al., 2006, Bailey et al., 2008 and Geor, 2009), it 
would be interesting to evaluate the consumption of dietary AGEs and their precursors that 





This study reports for the first time that plasma pentosidine concentrations are higher in 
ponies exhibiting clinical features of EMS and a recent history of/concurrent laminitis 
compared with ponies with no recent history of laminitis. These preliminary findings were 
obtained from a small sample of ponies in a single herd, thus further research considering 
other populations is needed to confirm the involvement of the glycoxidation pathway in the 
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 reported as % on dry matter basis  for cool season grass 
pasture in northern Virginia over grazing seasons. Data courtesy of Dr. Kibby Treiber. 
 
Month CP % Starch % WSC % Fructan % NDF% ADF % ESC % 
January 11.23 0.35 1.78 0 48.63 25.00 2.45 
March 9.65 0.45 0.85 0 47.35 24.40 1.20 
May 19.47 1.03 12.37 3.80 38.47 16.70 8.57 
July 18.05 0.93 6.73 0.05 49.88 22.60 6.68 
September 20.03 0.95 5.9 2.15 53.43 31.20 3.75 
 
CP, crude protein; WSC, water soluble carbohydrates; NDF, neutral detergent fibre; ADF, 
acid detergent fibre; ESC, ethanol soluble carbohydrates. 
a 
Data summarised for each month over three consecutive days of sampling during the first 2 
weeks of each month.  




Age, body weight, BCS, glucose, insulin, triglycerides, NEFA, pentosidine and basal 
proxies in never laminitic (NL) and laminitic ponies (LP). 
 
 NL  LP    
n 10  21    
 Mean SD Mean SD U P 
Age (years) 6.20 1.36 15.14 7.14 21.50 <0.001 
Body weight (Kg) 314.60 13.77 320.30 41.53 91.00 n.s. 
BCS  6.97 0.35 6.99 0.74 96.00 n.s. 
Pentosidine (pmol/mg protein) 5.26 0.79 9.75 0.98 43.00 <0.005 
RISQI [mU/L]
-0.5 
0.24 0.02 0.14 0.01 20.50 <0.001 
 Median IR Median IR   




NEFA (mEq/L) 0.35 0.07 to 0.53 0.24 0.06 to 0.34 75.50 n.s. 
TG (mmol/L) 0.51 0.36 to 0.62 0.65 0.46 to 0.85 60.00 0.03 
Insulin (pmol/L) 137.80 82.05 to 169.00 315.20 234.08 to 1027.00 18.00 <0.001 
I:G ratio 0.19 0.13 to 0.26 0.51 0.38 to 1.40 14.00 <0.001 
 
BCS, body condition score; RISQI, reciprocal of the square root of insulin; NEFA, non-
esterified fatty acids; I:G, insulin to glucose ratio; TG, triglyceride; n.s., not significant, 









Fig. 1. Correlation between plasma pentosidine (PENT) and RISQI score in never laminitic 
(NL,〇 circles) and laminitic ponies (LP,● dot points). The Spearman's correlation coefficient 
was calculated using Graph Pad software; a significant negative correlation was observed 
(P=0.0005, rs = -0.56). 
 
 
 
